[185 Pages Report] The Porcine Vaccines Market size was estimated at USD 1.71 billion in 2023 and expected to reach USD 1.82 billion in 2024, at a CAGR 6.72% to reach USD 2.70 billion by 2030.
Porcine vaccines are immunological preparations designed to prevent various swine diseases in pigs. These vaccines are created to stimulate the porcine immune system, enabling it to develop defenses against pathogens such as viruses or bacteria that can cause illness. By mimicking the infection, they prepare the swine’s body to recognize and combat the actual pathogens should they be encountered in the future. The rise in the incidence of swine diseases and the growing global consumption of pork products are major driving factors behind the need for porcine vaccines. Furthermore, supportive government initiatives, including subsidies and awareness programs, have encouraged the use of vaccines. However, the need for a cold chain infrastructure creates logistical challenges, particularly in developing countries. Furthermore, the variability in the immune response of different pig breeds can impact vaccine effectiveness and create hurdles for the development and adoption of porcine vaccines. However, key players are exploring novel technologies such as nanotechnology, gene editing strategies, and precision medicine to ensure the development of customized vaccines that can overcome the performance challenges of porcine vaccines. Moreover, investigating new adjuvants to enhance immune response without compromising safety and developing needle-free administration could improve vaccine uptake and reduce stress on animals.
Technology: Growing innovations in recombinant vaccines due to advancements in genetic engineering and molecular biology technologies
A conjugate vaccine refers to a vaccine that is composed of a polysaccharide antigen fused or conjugated to a carrier molecule. In porcine vaccines, they are used to target diseases where the pathogens have polysaccharide coatings, which are generally poorly immunogenic. Such vaccines are especially useful for targeting diseases caused by bacteria with polysaccharide capsules. DNA vaccines utilize genetic material to induce an immune response. When the genetic material enters the animal’s cells, it is used to produce the antigen which in turn stimulates the immune system. These vaccines are still relatively novel in the veterinary field. Such vaccines may be preferred for their potential for rapid development and their ability to provide long-lasting immunity without the need for adjuvants. Inactivated vaccines contain pathogens that have been killed. They cannot cause an infection but still prompt an immune response. These vaccines are considered safe and stable. Live attenuated vaccines contain a live and weakened version of the pathogen. They closely mimic a natural infection and typically provide strong, long-lasting immunity. Recombinant vaccines use a piece of the pathogen (typically a protein) created using the techniques of genetic engineering. This component is used to stimulate an immune response without the risk of introducing a live pathogen. Toxoid vaccines are created by inactivating the toxins produced by certain bacteria. These vaccines are used to protect against diseases that are caused not by the bacteria itself, but by the toxins they produce. Toxoid vaccines are the preferred option when addressing illnesses where the primary concern is the bacterial toxin.
End User: Growing need for mass vaccination programs in the hog/pig production farm
The hog/pig production farm sector includes entities involved in raising pigs primarily for meat production. The need for vaccines in such farms is driven by the requirement to maintain a disease-free environment, enhance growth performance of the animals, and ultimately increase farmer profitability. Hog and pig production farms typically require vaccines thar can address a wide spectrum of common swine diseases, such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and foot and mouth disease, among others. Veterinary clinics and hospitals cater to a broad range of animals, including pigs. These facilities generally encounter pigs and other swine for vaccinations as part of routine health checks or specific disease outbreaks. The vaccine preferences in this environment are for products with broad-spectrum efficacy and rapid onset of immunity. Since these facilities might be dealing with individual animals or small herds, they often prefer single-dose, easy-to-administer vaccines that are also available in smaller package sizes.
Regional Insights
In the Americas region, particularly the U.S. and Canada, the porcine vaccine market is well-established due to the extensive pig farming industry and a strong emphasis on animal health management. The country sees a significant consumer need for vaccinations against prevalent diseases such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and others. Producers often adopt the latest vaccines, and purchasing behavior indicates a readiness to invest in advanced solutions for swine herds. Recent research in the U.S. has focused on developing vaccines with improved efficacy and longer immunity periods. Investments in biotechnology companies and government initiatives such as the Veterinary Biologics Program under the United States Department of Agriculture(USDA)-Animal & Plant Health Inspection Service(APHIS) reflect ongoing efforts to strengthen the sector. The EMEA countries represent a diverse market with stringent animal welfare and health regulations. The European consumer requires vaccines that comply with high safety standards, leading to a demand for quality-assured vaccines. The EU’s Horizon 2020 program has seen substantial investments in research addressing swine diseases, which propels the development of new and efficient vaccines. In the APAC region, China represents a highly evolved market for pig meat, thereby accentuating the need for porcine markets. India, with an emerging pig farming industry in the APAC region, presents a moderate but growing demand for porcine vaccines. Consumer needs revolve around affordable and accessible vaccines due to cost-sensitive purchasing behaviors. The government has been encouraging the growth of the swine industry through initiatives that provide support for vaccinations and animal health programs.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Porcine Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Porcine Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Porcine Vaccines Market, highlighting leading vendors and their innovative profiles. These include Aptimmune Biologics, Inc., Arko Laboratories, AVAC Vietnam Joint Stock Company, Bayer AG, Bimeda Holdings PLC, Biog?nesis Bag? S.A., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Endovac Animal Health, FATRO S.p.A., Formosa Biomedical Inc., Genvax Technologies, Inc., HIPRA, S.A., Indian Immunologicals Ltd., KM Biologics Co., Ltd., Kyoto Biken Laboratories, Inc., Malaysian Vaccines & Pharmaceuticals Sdn Bhd., Medgene Labs, Merck & Co., Inc., Nisseiken Co., Ltd., PBS Animal Health, Phibro Animal Health Corporation, Virbac SA, Yenher Agro-Products Sdn. Bhd., and Zoetis Inc..
Market Segmentation & Coverage
This research report categorizes the Porcine Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Indication
- Arthritis
- Diarrhea
- Porcine Circovirus Associated Disease
- Porcine Reproductive & Respiratory Syndrome
- Swine Influenza
- Technology
- Conjugate Vaccines
- DNA Vaccines
- Inactivated Vaccines
- Live attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- End User
- Hog/Pig Production Farm
- Veterinary Clinics/Hospitals
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Porcine Vaccines Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Porcine Vaccines Market?
- What are the technology trends and regulatory frameworks in the Porcine Vaccines Market?
- What is the market share of the leading vendors in the Porcine Vaccines Market?
- Which modes and strategic moves are suitable for entering the Porcine Vaccines Market?
US $
Euro €
GBP £
